Get the Stockscreener App
29.50
1.04%
-0.285
Edgewise Therapeutics Inc stock is traded at $29.50, with a volume of 471.02K.
It is down -1.04% in the last 24 hours and up +35.53% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$29.78
Open:
$29.55
24h Volume:
471.02K
Relative Volume:
0.34
Market Cap:
$3.12B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-19.03
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
+7.59%
1M Performance:
+35.53%
6M Performance:
+104.79%
1Y Performance:
+9.15%
1-Day Range:
$29.40
$30.25
1-Week Range:
$26.42
$30.25
52-Week Range:
$10.60
$30.48
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
29.48 | 3.15B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Retail Trends: Is Edgewise Therapeutics Inc trading at a discountJuly 2025 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Understanding the Setup: (EWTX) and Scalable Risk - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
Edgewise Therapeutics, Inc. (EWTX) outlines priorities for 2026 - MSN
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy? - Sahm
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed 2026 Clinical Milestone Update - Sahm
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX - TechStock²
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 7%Should You Buy? - MarketBeat
Technical Analysis: Is Edgewise Therapeutics Inc subject to activist investor interest2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update - Yahoo Finance
Edgewise Therapeutics (EWTX) Stock Analysis: A 58% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - Sahm
Edgewise Therapeutics provides corporate updates and highlights priorities for 2026 - marketscreener.com
Sectors Review: What analysts say about Edgewise Therapeutics Inc stock - baoquankhu1.vn
Why Edgewise Therapeutics Inc stock could benefit from AI revolutionPortfolio Update Report & Safe Entry Zone Tips - Bộ Nội Vụ
Can Edgewise Therapeutics Inc. stock double in next 5 yearsJuly 2025 Highlights & Daily Price Action Insights - ulpravda.ru
Can Edgewise Therapeutics Inc. stock continue upward trendWatch List & Low Risk Profit Maximizing Plans - ulpravda.ru
Momentum Shift: Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - Улправда
Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - Улправда
Edgewise Therapeutics rises 15.5% - MSN
Will Sure Ventures Plc (08F) stock extend growth storyRate Cut & Intraday High Probability Alerts - ulpravda.ru
Is Edgewise Therapeutics Inc. stock affected by interest rate hikesEarnings Performance Report & Free Verified High Yield Trade Plans - ulpravda.ru
How Edgewise Therapeutics Inc. stock compares to market leadersJuly 2025 Sentiment & Stock Portfolio Risk Control - Улправда
Will Edgewise Therapeutics Inc. stock remain a Wall Street favorite2025 Stock Rankings & Daily Growth Stock Investment Tips - Улправда
About Us | Laser Focus WorldEdgewise Therapeutics, Inc.Common Stock (Nasdaq:EWTX) Stock Quote - FinancialContent
Why Edgewise Therapeutics Inc. stock is seen as undervaluedJuly 2025 Earnings & Accurate Intraday Trading Signals - Улправда
Why Edgewise Therapeutics Inc. stock could benefit from AI revolutionSwing Trade & Technical Pattern Based Signals - Улправда
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - MSN
A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update - Sahm
Edgewise Therapeutics CEO to outline 2026 goals at JPMorgan event - Traders Union
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 61.93% Upside Potential in Biotech - DirectorsTalk Interviews
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT - MSN
Edgewise Therapeutics rises 20.3% - MSN
Edgewise Therapeutics Earnings Notes - Trefis
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Why Edgewise Therapeutics stock rocked the market today - MSN
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise rises on mid-stage trial data for heart disease therapy - MSN
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):